Close
UCL in the News: The Story of a Nanoparticle Start-Up
25 July 2007
In this exclusive interview, Fintan Walton talks to Tom Rademacher [UCL Immunology & Molecular Pathology], President of Midatech, about the formation of the biotech, Professor Rademacher's fifth start-up company.
Tom discusses Midatech's business model, and why a centralised group company structure with three fully owned subsidiaries suited the development of its technology. He also talks in depth about the science behind the company's nanoparticle technology, as well as its applications in therapeutics, diagnostics and surface coatings. …
PharmaTelevision.com
Follow us
